Valneva SE - Product Pipeline Review - 2015

Published: Oct, 2015 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Valneva SE - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Valneva SE - Product Pipeline Review - 2015', provides an overview of the Valneva SE's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Valneva SE's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Valneva SE including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Valneva SE's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Valneva SE's pipeline products

Reasons to Buy

- Evaluate Valneva SE's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Valneva SE in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Valneva SE's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Valneva SE and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Valneva SE
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Valneva SE and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents
 2
List of Tables 4
List of Figures 4
Valneva SE Snapshot 5
Valneva SE Overview 5
Key Information 5
Key Facts 5
Valneva SE - Research and Development Overview 6
Key Therapeutic Areas 6
Valneva SE - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Valneva SE - Pipeline Products Glance 14
Valneva SE - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Valneva SE - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Valneva SE - Drug Profiles 17
VLA-43 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Vaccine for Undisclosed Indication 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
VLA-84 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
VLA-15 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Antibodies for Pneumococcus Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Valneva SE - Pipeline Analysis 23
Valneva SE - Pipeline Products by Target 23
Valneva SE - Pipeline Products by Route of Administration 24
Valneva SE - Pipeline Products by Molecule Type 25
Valneva SE - Recent Pipeline Updates 26
Valneva SE - Dormant Projects 30
Valneva SE - Discontinued Pipeline Products 31
Discontinued Pipeline Product Profiles 31
IC-41 31
IC-47 31
VLS-732 31
VLS-801 31
Valneva SE - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables

Valneva SE, Key Information 5
Valneva SE, Key Facts 5
Valneva SE - Pipeline by Indication, 2015 7
Valneva SE - Pipeline by Stage of Development, 2015 8
Valneva SE - Monotherapy Products in Pipeline, 2015 9
Valneva SE - Partnered Products in Pipeline, 2015 10
Valneva SE - Partnered Products/ Combination Treatment Modalities, 2015 11
Valneva SE - Out-Licensed Products in Pipeline, 2015 12
Valneva SE - Out-Licensed Products/ Combination Treatment Modalities, 2015 13
Valneva SE - Phase II, 2015 14
Valneva SE - Preclinical, 2015 15
Valneva SE - Discovery, 2015 16
Valneva SE - Pipeline by Target, 2015 23
Valneva SE - Pipeline by Route of Administration, 2015 24
Valneva SE - Pipeline by Molecule Type, 2015 25
Valneva SE - Recent Pipeline Updates, 2015 26
Valneva SE - Dormant Developmental Projects,2015 30
Valneva SE - Discontinued Pipeline Products, 2015 31
Valneva SE, Subsidiaries 32